IL18 and infection: To determine whether IL-18 was playing a key role in driving immunopathology during genital HSV-2 infection, we therapeutically administered an IL-18-neutralizing antibody directly at the site of infection to HSV-2-infected animals starting at 3 d.p.i. in order to promote sufficient antibody concentration and activity in the relevant tissue.